Evaluation of the safety of recombinant P-selectin glycoprotein ligand-immunoglobulin G fusion protein in experimental models of localized and systemic infection
Sm. Opal et al., Evaluation of the safety of recombinant P-selectin glycoprotein ligand-immunoglobulin G fusion protein in experimental models of localized and systemic infection, SHOCK, 15(4), 2001, pp. 285-290
Citations number
25
Categorie Soggetti
Aneshtesia & Intensive Care","Cardiovascular & Hematology Research
P-selectin is a major component in the early interaction between platelets,
endothelial cells, and inflammatory cells in the initial phases of the inn
ate immune response. The major ligand for P-selectin is P-selectin glycopro
tein ligand-1 (PSGL-1) and this ligand is expressed on the surface of monoc
yte, lymphocyte, and neutrophil membranes. A truncated form of recombinant
human P-selectin glycoprotein ligand-1 has been covalently linked to immuno
globulin G (rPSGL-Ig) and this fusion peptide functions as a competitive in
hibitor of PSGL-1. As an inhibitor of neutrophil-endothelial cell adherence
, rPSGL-Ig is in early clinical development for the treatment of ischemia r
eperfusion injury. To determine the potential for deleterious effects from
inhibition in P-selectin-mediated neutrophil attachment in the presence of
bacterial infection, the effects of therapeutic doses of rPSGL-Ig were test
ed in three standard laboratory sepsis models. The experimental models incl
uded: the murine systemic Listeria monocytogenes infection model, the Pseud
omonas aeruginosa bacteremia model in neutropenic rats, and the cecal ligat
ion and puncture (CLP)-induced peritonitis model in rats. Recombinant human
PSGL-Ig had no adverse effects on mortality or immune clearance in systemi
c bacterial infection in any of the three infection models. The PSGL-1 inhi
bitor did significantly decrease local neutrophil infiltration and bacteria
l clearance in the peritoneum following CLP, but this did not increase the
systemic levels of proinflammatory cytokines, the quantitative levels of ba
cteremia, or the overall mortality rate following CLP. The results indicate
that rPSGL-Ig did not exacerbate infection in these experimental sepsis mo
dels.